TY  - JOUR
T1  - Incorrect data in: Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis
Y1  - 2009/03/25
N1  - 10.1001/jama.2009.290
JO  - JAMA
SP  - 1227
EP  - 1230
VL  - 301
IS  - 12
N2  - 
On page 1439, in the abstract, the Data Synthesis section should read “After a detailed screening of 103 articles, 17 trials enrolling 13 645 patients were analyzed. Follow-up duration ranged from 6 weeks to 5 years. Cardiovascular death, MI, or stroke occurred in 134 of 6984 patients (1.9%) receiving inhaled anticholinergics and 83 of 6661 patients (1.2%) receiving control therapy (RR, 1.60 [95% confidence interval {CI}, 1.22-2.10]; P < .001, I2 = 0%). Among individual components of the primary end point, inhaled anticholinergics significantly increased the risk of MI (RR, 1.52 [95% CI, 1.04-2.22]; P = .03, I2 = 0%) and cardiovascular death (RR, 1.92 [95% CI, 1.23-3.00]; P = .004, I2 = 0%) without a statistically significant increase in the risk of stroke (RR, 1.46 [95% CI, 0.81-2.62]; P = .20, I2 = 0%). All-cause mortality was reported in 146 of the patients treated with inhaled anticholinergics (2.2%) and 108 of the control patients (1.7%) (RR, 1.29 [95% CI, 1.00-1.65]; P = .05, I2 = 0%). A sensitivity analysis restricted to 5 long-term trials (>6 months) confirmed the significantly increased risk of cardiovascular death, MI, or stroke (2.9% of patients treated with anticholinergics vs 1.8% of the control patients; RR, 1.73 [95% CI, 1.27-2.35]; P < .001, I2 = 0%).

SN  - 0098-7484
M3  - doi: 10.1001/jama.2009.290
UR  - http://dx.doi.org/10.1001/jama.2009.290
ER  -